BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 28132785)

  • 1. Allosteric Mutant IDH1 Inhibitors Reveal Mechanisms for IDH1 Mutant and Isoform Selectivity.
    Xie X; Baird D; Bowen K; Capka V; Chen J; Chenail G; Cho Y; Dooley J; Farsidjani A; Fortin P; Kohls D; Kulathila R; Lin F; McKay D; Rodrigues L; Sage D; Touré BB; van der Plas S; Wright K; Xu M; Yin H; Levell J; Pagliarini RA
    Structure; 2017 Mar; 25(3):506-513. PubMed ID: 28132785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule.
    Deng G; Shen J; Yin M; McManus J; Mathieu M; Gee P; He T; Shi C; Bedel O; McLean LR; Le-Strat F; Zhang Y; Marquette JP; Gao Q; Zhang B; Rak A; Hoffmann D; Rooney E; Vassort A; Englaro W; Li Y; Patel V; Adrian F; Gross S; Wiederschain D; Cheng H; Licht S
    J Biol Chem; 2015 Jan; 290(2):762-74. PubMed ID: 25391653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
    Ma R; Yun CH
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2912-2917. PubMed ID: 30131249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer.
    Brooks E; Wu X; Hanel A; Nguyen S; Wang J; Zhang JH; Harrison A; Zhang W
    J Biomol Screen; 2014 Sep; 19(8):1193-200. PubMed ID: 24980596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.
    Wang F; Travins J; DeLaBarre B; Penard-Lacronique V; Schalm S; Hansen E; Straley K; Kernytsky A; Liu W; Gliser C; Yang H; Gross S; Artin E; Saada V; Mylonas E; Quivoron C; Popovici-Muller J; Saunders JO; Salituro FG; Yan S; Murray S; Wei W; Gao Y; Dang L; Dorsch M; Agresta S; Schenkein DP; Biller SA; Su SM; de Botton S; Yen KE
    Science; 2013 May; 340(6132):622-6. PubMed ID: 23558173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1).
    Kang CH; Choi SU; Son YH; Lee HK; Jeong HG; Yun CS; Ahn S; Park CH
    Anticancer Res; 2020 Sep; 40(9):4929-4935. PubMed ID: 32878781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.
    Wen H; Cho HR; Yun T; Kim H; Park CK; Lee SH; Choi SH; Park S
    J Neurochem; 2015 Jan; 132(2):183-93. PubMed ID: 25251602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.
    Davis MI; Gross S; Shen M; Straley KS; Pragani R; Lea WA; Popovici-Muller J; DeLaBarre B; Artin E; Thorne N; Auld DS; Li Z; Dang L; Boxer MB; Simeonov A
    J Biol Chem; 2014 May; 289(20):13717-25. PubMed ID: 24668804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.
    Okoye-Okafor UC; Bartholdy B; Cartier J; Gao EN; Pietrak B; Rendina AR; Rominger C; Quinn C; Smallwood A; Wiggall KJ; Reif AJ; Schmidt SJ; Qi H; Zhao H; Joberty G; Faelth-Savitski M; Bantscheff M; Drewes G; Duraiswami C; Brady P; Groy A; Narayanagari SR; Antony-Debre I; Mitchell K; Wang HR; Kao YR; Christopeit M; Carvajal L; Barreyro L; Paietta E; Makishima H; Will B; Concha N; Adams ND; Schwartz B; McCabe MT; Maciejewski J; Verma A; Steidl U
    Nat Chem Biol; 2015 Nov; 11(11):878-86. PubMed ID: 26436839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Water Networks and Correlated Motions in Mutant Isocitrate Dehydrogenase 1 (IDH1) Are Critical for Allosteric Inhibitor Binding and Activity.
    Chambers JM; Miller W; Quichocho G; Upadhye V; Matteo DA; Bobkov AA; Sohl CD; Schiffer JM
    Biochemistry; 2020 Feb; 59(4):479-490. PubMed ID: 31869219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetic analysis of NAD(+)-isocitrate dehydrogenase with altered isocitrate binding sites: contribution of IDH1 and IDH2 subunits to regulation and catalysis.
    Cupp JR; McAlister-Henn L
    Biochemistry; 1993 Sep; 32(36):9323-8. PubMed ID: 8369302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors.
    Verdura S; Cuyàs E; Lozano-Sánchez J; Bastidas-Velez C; Llorach-Parés L; Fernández-Arroyo S; Hernández-Aguilera A; Joven J; Nonell-Canals A; Bosch-Barrera J; Martin-Castillo B; Vellon L; Sanchez-Martinez M; Segura-Carretero A; Menendez JA
    Carcinogenesis; 2019 Mar; 40(1):27-40. PubMed ID: 30428017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Insights for Inhibiting Mutant Heterodimer IDH1
    Juritz EI; Bascur JP; Almonacid DE; González-Nilo FD
    Mol Diagn Ther; 2018 Jun; 22(3):369-380. PubMed ID: 29651790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications.
    Lee S; Urman A; Desai P
    Leuk Lymphoma; 2019 Nov; 60(11):2635-2645. PubMed ID: 30958073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allosteric inhibitor remotely modulates the conformation of the orthestric pockets in mutant IDH2/R140Q.
    Chen J; Yang J; Sun X; Wang Z; Cheng X; Lu W; Cai X; Hu C; Shen X; Cao P
    Sci Rep; 2017 Nov; 7(1):16458. PubMed ID: 29184081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
    Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
    PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based discovery of IHMT-IDH1-053 as a potent irreversible IDH1 mutant selective inhibitor.
    Liang Q; Wang B; Zou F; Guo G; Wang W; Wang W; Liu Q; Shen L; Hu C; Wang W; Wang A; Huang T; He Y; Xia R; Ge J; Liu J; Liu Q
    Eur J Med Chem; 2023 Aug; 256():115411. PubMed ID: 37209613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
    Dang L; Su SM
    Annu Rev Biochem; 2017 Jun; 86():305-331. PubMed ID: 28375741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening.
    Zou F; Pusch S; Hua J; Ma T; Yang L; Zhu Q; Xu Y; Gu Y; von Deimling A; Zha X
    Bioorg Med Chem Lett; 2018 Feb; 28(3):388-393. PubMed ID: 29290542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
    Ward PS; Lu C; Cross JR; Abdel-Wahab O; Levine RL; Schwartz GK; Thompson CB
    J Biol Chem; 2013 Feb; 288(6):3804-15. PubMed ID: 23264629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.